jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Sept. 05, 2023

Jan. 16, 2025

jRCT2042230075

TCD-12261 used for wide-necked ceberal aneurysm coil embolization : A multicenter, single arm study

TCD-12261

Chiaki Chiba

Terumo Corporation

Tokyo Opera City Tower 49F, 3-20-2, Nishi-shinjuku, Shinjuku-ku, Tokyo

+81-3-6742-8500

TERUMO_CD@terumo.co.jp

Chiaki chiba

Terumo Corporation

Tokyo Opera City Tower 49F, 3-20-2, Nishi-shinjuku, Shinjuku-ku,Tokyo

+81-3-6742-8500

TERUMO_CD@terumo.co.jp

Not Recruiting

Sept. 05, 2023

40

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

Subjects must meet the following criteria to be included in the study:
(1)Uunruptured, wide-necked (neck => 4mm or dome/neck ratio <2) intracranial, a diameter => 5 mm aneurysm, the parent artery is 2.0 - 4.0 mm.
(2)Difficult to treat with surgery or only embolization coils.
(3)Age is >= 18, =< 80 years at the time of informed consent.
(4)Patients understand the purpose and contents and then provide a signed informed consent form by his/her own will.
(5)follwing the rules, of this trial such as trial visit scedules, examinations.

At pre-registraton, patients will be excluded from the study for:
(1)Having intracranial masses such as tumors, abscesses, or other infections. Undergoing radiation therapy for head or neck tumors or sarcomas.
(2)History of bleeding diathesis, abnormal coagulation. Refusing a blood transfusion.
(3)Drugs required for EVT are contraindicated. Having allergies of acontrast agents. Needed Usage restrictions of acontrast agents.
(4)Hypersensitivity to metal, such as nickel-titanium and metal jewelry
(5)Life expectancy less than 6 months.
(6)Current participation in clinical study that has not completed primary endpoint evaluation or studies that may have an impact on the evaluation of this clinical trial.
(7)Have/will receive treatments that may have an impact on the evaluation of this clinil trial within 3 months prior to TCD-12261 surgery.
(8)History of heart disease or complication highly relevant to atrial fibrillation and cardiogenic embolism.
(9)Active bacterial infections.
(10)Pre-existing stents in place at the target aneurysm.
(11)Currently pregnant, planning to become pregnant during the course of the study.
(12)Considered ineligible for the study by the investigator.

At registraton, patients will be excluded from the study for:
(13)Uunruptured, wide-necked (neck < 4mm or dome/neck ratio >2) intracranial, a diameter < 5 mm aneurysm, the parent artery < 2.0mm or > 4.0 mm.
(14)Considered ineligible for the EVT treatment by the investigator.
(15)Ipsilateral arteriovenous malformations.
(16)Having other aneurysms needed to treat during the course of the study.
(17)Needed 2 or more stents to treat target aneurysm.

18age 0month 0week old over
80age old under

Both

Unruptured, wide-necked intracranial aneurysm

Intravascular placement of the TCD-12261

Clinical Success
(1)Accuracy of placement to an aneurysm neck
(2)Patency of the stent
(3)Coils remain inside the aneurysm
(4)No major adverse cerebrovascular event related to the procedure or device within 30 days after procedure

Terumo Corporation
Aichi medical University Institutional Review Board
Yazakokarimata 1-1, Nagakute, Aichi

+81-561-62-3311

chiken@aichi-med-u.ac.jp
Approval

Sept. 19, 2023

No

none

History of Changes

No Publication date
3 Jan. 16, 2025 (this page) Changes
2 Oct. 18, 2023 Detail Changes
1 Sept. 05, 2023 Detail